Novel immune-cell targeted IL2v to deliver IL-2R signaling to tumor reactive T cells via PD-1 whilst blocking the PD-1 pathway

被引：0

作者：

Deak, Laura Codarri ^{[1
]}

Nicolini, Valeria ^{[1
]}

Lauener, Laura ^{[1
]}

Seeber, Stefan ^{[2
]}

Richard, Marine ^{[1
]}

Bommer, Esther ^{[1
]}

Karagianni, Maria ^{[1
]}

Sam, Johannes ^{[1
]}

Schlenker, Ramona ^{[2
]}

Mariani, Marisa ^{[1
]}

Schwalie, Petra ^{[3
]}

Herter, Sylvia ^{[1
]}

Bacac, Marina ^{[1
]}

Waldhauer, Inja ^{[1
]}

Freimoser-Grundschober, Anne ^{[1
]}

Teichgraber, Volker ^{[1
]}

Klein, Christian ^{[1
]}

Umana, Pablo ^{[1
]}

机构：

[1] Roche Innovat Ctr Zurich, Zurich, Switzerland

[2] Roche Innovat Ctr Munich, Munich, Germany

[3] Roche Innovat Ctr Basel, Basel, Switzerland

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P615

引用

页数：1

共 50 条

[31] DIACYLGLYCEROL KINASE ζ LIMITS IL-2-DEPENDENT CONTROL OF PD-1 EXPRESSION IN TUMOR-INFILTRATING T LYMPHOCYTES
Arranz-Nicolas, Javier
Rodriguez-Rodriguez, Cristina
Liebana, Rosa
Leitner, Judith
Avila-Flores, Antonia
Steinberger, Peter
Merida, Isabel
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A318 - A318
[32] PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105
Wang, Xi
Lai, Zhiheng
Pang, Yanyang
Sun, Qinghui
Yang, Wenli
Wang, Wu
HELIYON, 2023, 9 (01)
[33] Tumor Cell-Derived TGFb1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA
Wu, Pengfei
Geng, Bo
Chen, Qun
Zhao, Enyang
Liu, Jiang
Sun, Chen
Zha, Caijun
Shao, Yong
You, Bosen
Zhang, Wenfu
Li, Lulu
Meng, Xiangqi
Cai, Jinquan
Li, Xuedong
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (12) : 1470 - 1484
[34] A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease
Liu, Chao
Sun, Bing
Xu, Bin
Meng, Xiangying
Li, Lan
Cong, Yang
Liu, Jiannan
Wang, Qian
Xuan, Liang
Song, Qibin
Wu, Shikai
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1749 - 1761
[35] IL-2 decreased PU.1 and PD-1 expression in NK-cells in NSCLC patients
Hohenberger, Katja
Trufa, Denis I.
Geppert, Carol-Immanuel
Rieker, Ralf J.
Sirbu, Horia
Finotto, Susetta
JOURNAL OF IMMUNOLOGY, 2021, 206
[36] Tumor regression with CD8+T cells in tumor micro-environment and central immune system following PD-1 mAb plus IL-2 treatment
Lin, J.
Zheng, T.
Li, X.
Wen, H.
Zhang, Q.
Fang, S.
Jin, R.
Deng, Q.
Xu, Y.
Chen, Z.
Cao, P.
Lin, X.
Lin, S.
Xiong, J.
Lao, H.
Yang, J.
Morton, L.
Yueh, B.
Lin, J.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 378 - 378
[37] IL-2 synergizes with PD-1/PD-L1 blockade via CD28/CHK1 pathway to enhance CD81 T cell responses in lung squamous cell carcinoma
Huang, S-M.
Wu, S-P.
Liao, R-Q.
Dong, Z-Y.
Tu, H.
Xie, Z.
Su, J.
Yang, J-J.
Zhang, X.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2016, 27
[38] IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Sun, Zhaojun
Fourcade, Julien
Pagliano, Ornella
Chauvin, Joe-Marc
Sander, Cindy
Kirkwood, John M.
Zarour, Hassane M.
CANCER RESEARCH, 2015, 75 (08) : 1635 - 1644
[39] PD-1 in balancing expansion of effector T cells and attrition of memory T cell during tumor-reactive T cell responses
Mao, Zhiming
Hirdler, Jacob
Harrington, Susan
Liu, Xin
Gicobi, Joanina
Dellacecca, Emilia
Hsu, Michelle A.
Zhang, Wenjing
Park, Sean
Dong, Haidong
JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
[40] Th2 cell intrinsic tolerance determines susceptibility to helminth infection via the PD-1/PD-L2 pathway
van der Werf, N.
Redpath, S.
Azuma, M.
Yagita, H.
Taylor, M.
IMMUNOLOGY, 2013, 140 : 107 - 107

← 1 2 3 4 5 →